Skip to main content
Regeneron8-K: Product launch

FDA Approves Pasatru for Treatment of Fibrodysplasia Ossificans Progressiva

Source: Autobound Signal API · 94 signals tracked for Regeneron · updated

Get Regeneron's live signals in Claude or ChatGPT, or by API

AskWhat changed at Regeneron this week? Use Autobound signals for regeneron.com.

What happened

In August 2026, the FDA approved Pasatru (garetosmab) to reduce new heterotopic ossification lesions and flare-ups in adults with FOP.

Source

SEC EDGAROct 30, 2026

Current report (Form 8-K)

Regeneron 8-K

Filing excerpt

In August 2026, the FDA approved Pasatru to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.

sec.gov/Archives/edgar/data/872589/000087258926000032/regn-20261030.htmRead the full source

Other signals in this filing (2)

Extracted by Autobound

From the Signal API record
Signal
8-K: Product launch

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
10/30
Filed
Oct 30, 2026

The full record

From the Signal API record

Details

CIK
872589
Accession number
0000872589-26-000032
Timeframe
Last year
Filing year
2026
Why it matters
Go-to-market support
Signal category
Strategic

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
75%
Sentiment
Positive
Detected
Nov 3, 2026
signal_type
sec-8k
signal_subtype
productLaunch

Use this data

Get every 8-K signal for Regeneron and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/ffd4f866-3f82-4312-aaf9-cfc8d0234920 returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.

{
  "signal_id": "ffd4f866-3f82-4312-aaf9-cfc8d0234920",
  "signal_type": "sec-8k",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-11-03T07:04:59.413+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "detail": "In August 2026, the FDA approved Pasatru (garetosmab) to reduce new heterotopic ossification lesions and flare-ups in adults with FOP. Commercialization of a newly approved therapy may create demand for patient engagement, specialty distribution, and marketing technology.",
    "metrics": {
      "timeframe": "last_year"
    },
    "summary": "FDA Approves Pasatru for Treatment of Fibrodysplasia Ossificans Progressiva",
    "excerpts": "In August 2026, the FDA approved Pasatru to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.",
    "relevance": 0.75,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/regn-20261030.htm",
    "filing_date": "2026-10-30",
    "filing_year": 2026,
    "fiscal_year_end": "10/30",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.